[The prognostic value of flow cytometry in prostatic cancer].
DNA quantitation by flow cytometry was made in 36 patients with morphologically diagnosed prostatic cancer (PC) in stage II, III and IV (4, 14 and 18 patients, respectively). All the patients received adequate treatment. Aneuploid tumours were found in 25 patients (group 1), diploid ones in 11 patients (group 2). A 3-year survival in group 1 made up 65.5%, in group 2 all the patients survived 3 years. The recurrence-free survival was 22.2% and 78.8%, respectively. The above findings make it possible to regard flow cytometry DNA estimation as a reliable prognostic indication in PC.